Drug update

Cariprazine: a third-generation antipsychotic with a twist

Drug update

Cariprazine: a third-generation antipsychotic with a twist

JUDITH D. HOPE, NICHOLAS A. KEKS

Figures

© FRESHIDEA/STOCK.ADOBE.COM
© FRESHIDEA/STOCK.ADOBE.COM

Abstract

Cariprazine is a new atypical antipsychotic medication with a similar side effect profile to aripiprazole and brexpiprazole. It has a low risk of weight gain and sedation, but akathisia can be troublesome. Cariprazine is effective in the treatment of schizophrenia and may be particularly beneficial for the negative symptoms of this disorder. It can also be useful in people with partial adherence because of its long half-life.

Article Extract

In Australia, schizophrenia and related disorders affect 0.3% of the population and are associated with functional disability, physical morbidity and increased mortality.1 GPs have a key role in the treatment of patients with schizophrenia, particularly in managing physical health and monitoring and managing mental state.2 Antipsychotic medication, although a cornerstone of treatment for schizophrenia, can cause serious adverse effects which need to be monitored and managed. In addition, psychosocial interventions are crucial for the goal of recovery from illness.3